- OPTR presented 8/10 at the Canaccord Genuity conference - my quick notes are below. Click here for the full OPTR research page for more info on Dificid (fidaxomycin, a recently approved antibiotic for C. difficile associated diarrhea or CDAD)
- EU decision expected 4q2011, leading to binding CHMP opinion 1q2012.
- Cash on hand is sufficient until breakeven point for Dificid (goal is to achieve this sooner than the 3 year average for new hosptial products)
- The 100 new sales reps came on board in May-July time frame, so their cost not entirely represented within 2q11 numbers
- Now starting the 4th week of launch, everything is going according to plan
- Most hospitals are making Dificid available before formal formulary approval. Expect such approvals by ye2011 in vast majority of institutions.
- Q3 2011 results will give initial view of launch
- EU decision is a milestone, but launch planning is mostly in partner Astellas's hands
- In future, expect OPTR to continue to expand geotgraphically, continued publications, potential news on IP as well
- q&a was at breakout session and not webcast